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Abstract
This study investigated if pretreatment ethyl glucuronide (EtG) levels corresponding to light
(100ng/mL), heavy (500ng/mL), and very heavy (1,000ng/mL) drinking predicted longest duration
of alcohol abstinence (LDA) and proportion of EtG-negative urine tests in 40 outpatients receiving
a 12-week EtG-based contingency management (CM) intervention for alcohol dependence. Only
the 500ng/mL cutoff was associated with significant differences in LDA and proportion of EtGnegative samples during CM. Those with a pre-treatment EtG<500ng/mL attained a LDA 2.3
(alcohol) to 2.9 (drugs) weeks longer than pre-treatment heavy drinkers. Results suggest pretreatment EtG cutoffs equivalent to heavy and very heavy drinking predict outcomes in CM.
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Contingency management (CM) is an intervention in which reinforcers, such as vouchers or
prizes, are provided when individuals demonstrate illicit drug abstinence, typically measured
multiple times per week.1 While numerous studies have documented the efficacy of CM for
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illicit drugs and cigarette smoking, research investigating CM as a treatment for alcohol use
disorders has been limited due to lack of a suitable alcohol biomarker to verify use for two
or more days.2,3 However, ethyl glucuronide (EtG), a hepatic metabolite of alcohol
detectable in urine, addresses this need.
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In a recent study, the EtG alcohol biomarker was used to verify abstinence in a randomized
controlled trial of CM for alcohol use disorders using a relatively low-cost EtG
immunoassay.4 In this trial, 79 adults diagnosed with alcohol dependence and serious mental
illness participated in 4-week pre-randomization observation period during which they
submitted urine samples for EtG testing three times each week. They were randomized to
receive 12-weeks of CM for EtG-negative urine samples (EtG<150ng/mL) and addiction
treatment attendance, or non-contingent reinforcement in which they received reinforcement
for submitting urine samples regardless of EtG results. Relative to controls, CM participants
were three times more likely to submit an alcohol-negative urine sample during treatment
and attained an average of 1.5 weeks of additional abstinence, as assessed by EtG.
While overall response to CM was positive, in previous studies pre-treatment drug-positive
urine tests are associated with lower levels of abstinence during CM. 5,6,7 These studies used
point-of-care urine drug tests, which provide limited information (positive/negative) with
which to predict CM treatment response. In contrast, the present study used an EtG
immunoassay, which provides continuous results from 0ng/mL to 2,000ng/mL. In our
previous work we have found that EtG cutoffs of 100ng/mL, 500ng/mL, and 1,000ng/mL
correspond to recent light, heavy, and very heavy drinking, respectively.8 Therefore, the EtG
immunoassay allows us to determine which of these clinically relevant EtG cutoffs best
predicts treatment outcomes.
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In this secondary analysis, we investigated whether an EtG cutoff that was comparable to
light, heavy or very heavy drinking best discriminated between those who did and did not
respond to the CM intervention, as assessed by longest duration of abstinence (LDA) from
alcohol and the odds of submitting an alcohol-negative EtG test during CM. Results could
allow clinicians to use EtG tests, including new point-of-care tests, to identify individuals
who are likely or unlikely to respond to CM.

Method
Participants
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Participants were adults enrolled in state-certified outpatient addiction treatment at a
multisite community mental health and addiction treatment agency, who met DSM-IV-TR
criteria for alcohol dependence, and schizophrenia, schizoaffective disorder, bipolar I or II,
or recurrent major depressive disorder as assessed by the MINI International
Neuropsychiatric Interview. Seventy-nine individuals were randomized. This secondary data
analysis included only those allocated to CM (n=40). Participants provided written informed
consent and procedures were approved by the University of Washington’s Human Subjects
Division.
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Study design
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Participants received treatment-as-usual including case management, medication
management, and housing and vocational services throughout the study. Upon enrollment
they participated in a 4-week pre-treatment observation period in which they received
reinforcers contingent on providing urine samples three times per week regardless of EtGresults. Participants who attended at least one visit during week 4 and provided at least one
EtG-positive urine sample were randomized.
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Participants randomized to CM (n=40) submitted urine samples for EtG testing three times
per week for 12 weeks. They engaged in the variable magnitude of reinforcement procedure
each time they tested negative for EtG (<150ng/mL). This involved making “prize draws”
from a bucket containing tokens representing different magnitudes of reinforcement.1 Prizes
included toiletries, clothing, grocery and retail gift cards, small kitchen appliances, and
electronics, (average total value earned by participants=$175.03, SD=$183.17). In addition,
every week, participants received gift cards for attending all ($10) or at least one ($5) of
their scheduled addiction treatment group sessions.
Measures
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Participants provided urine samples three times per week during pretreatment and CM.
Urine samples were analyzed onsite using the Diagnostic Reagents Incorporated EtGimmunoassay with a Thermo Fisher Indiko analyzer (Fremont, CA). Samples were
considered alcohol-negative if EtG<150ng/mL. Tests were conducted using EtG 100ng/mL,
500ng/mL, 1000ng/mL, 2000ng/mL, and Negative calibrators and 100ng/mL and 375ng/mL
controls. The cutoff was set at 150ng/mL, 50ng/mL above the lower limit of detection for
the EtG biomarker to allow for regular fluctuation in the Indiko instrumentation.
Calibrations occurred weekly. Participants were asked to avoid non-beverage sources of
ethanol (i.e., mouthwash and cough syrup).
Data analysis
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The average pre-treatment EtG score of each participant was calculated based on 12 pretreatment urine samples collected over 4-weeks. These mean scores were then recoded into
three different variables based on the following cutoff levels: <100ng/mL (yes/no),
<500ng/mL (yes/no), and <1,000ng/mL (yes/no). Longest duration of alcohol abstinence
(highest number of consecutive EtG-negative urine tests; missing tests were considered EtGpositive and ended the period of abstinence) was compared across each of the three cutoff
level variables using independent samples t-tests. We utilized generalized estimating
equations (GEE) to investigate whether pretreatment period average EtG level predicted
proportion of EtG-negative urine samples submitted during the CM phase. The main effect
of each cutoff level variable was investigated in three separate analyses. For GEE analyses
we present odds ratios, and 95% confidence intervals. The criterion for statistical
significance was set at alpha p<0.05. Analyses were conducted using IBM SPSS version 23.
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Results
As Figure 1 demonstrates, those who attained an average pretreatment EtG level <100
ng/mL did not differ in LDA (n=11, M=9.73, 95%CI=3.91–15.55) relative to those who had
an average pretreatment EtG>99 ng/mL (n=29, M=8.45, 95%CI=4.78–12.12), p=0.72.
Those with an average pretreatment EtG level below EtG<500ng/mL had a significantly
longer LDA (n=24, M=11.58, 95%CI=7.28–15.88), relative to those with a pretreatment
EtG>499ng/mL (n=16, M=4.63, 95%CI=1.26–8), p<0.05. Individuals who averaged
EtG<1,000ng/mL (n=31, M=10.32, 95%CI=6.79–13.85) did not attain a longer duration of
abstinence that than those with EtG>999ng/mL (n=9, M=3.56, 95%CI=−1.49–8.61),
p=0.071. For comparison, participants in the control condition attained an average LDA of
4.1 (95%CI=3.73–4.49).
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In GEE analyses, participants who attained a pretreatment EtG level <100ng/mL were 6.67
times more likely (95% CI=2.07–21.46) to submit EtG-negative urine samples in the
treatment period, relative to those with EtG>99ng/mL. When the 500 ng/mL cutoff was
examined, participants with pretreatment EtG<500ng/mL were 10.16 times more likely
(95% CI=3.58–28.84) to submit EtG-negative urine samples, relative to those who had an
average EtG>499ng/mL. Finally, those who attained a pretreatment EtG level <1000ng/mL
were 12.33 times more likely (95% CI=2.78–54.67) to submit EtG-negative samples,
compared to those with a pretreatment EtG>999ng/mL.

Discussion
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Because pre-treatment drug-positive urine tests are a strong predictor of treatment outcome,
particularly in CM, 5–7 we used EtG to identify a specific cutoff associated with CM
treatment response. The 500ng/mL cutoff was the only cutoff associated with both LDA and
proportion of EtG-negative samples submitted during CM. Participants who had a
pretreatment mean EtG>499ng/mL attained 2.3 fewer weeks of alcohol abstinence than
those with an EtG<500ng/mL, indicating that the CM intervention was ineffective for this
subsample. The LDA for this group was equal to that of participants in the control condition.
The 100ng/mL and 1,000ng/mL cutoffs were also associated with the proportion of EtG
samples submitted during CM. The strength of the association between mean pretreatment
EtG levels and EtG-negative results during treatment increased as the pretreatment EtG
cutoff increased (i.e. OR=6.61 at 100 ng/mL, OR=10.16 at 500ng/mL, OR=12.13 at
1,000ng/mL). Therefore, individuals with higher pretreatment EtG levels were less likely to
submit EtG samples consistent with abstinence during CM.
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Limitations include the relatively small sample size, restricting our ability to conduct more
sophisticated analyses in which we could account for other variables that might predict CM
outcomes. However, the effect of pre-treatment EtG levels on CM outcomes was large, and
likely to remain even after accounting for confounds. Other limitations include recruitment
from one site, the possibility that results may not generalize to adults without SMI,
feasibility issues of the benchtop analyzer needed to conduct EtG tests, and the limited
practicality of conducting multiple EtG tests prior to treatment (sensitivity analysis found the
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results of a single baseline EtG test were not associated with alcohol outcomes). Newly
available point-of-care EtG immunoassays with a cutoff of 500ng/mL would allow clinicians
to more feasibly identify CM responders vs. non-responders and implement CM.
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EtG can be used to identify those who are likely to respond to an abstinence-based CM
intervention for alcohol use disorders, with 500ng/mL predicting LDA and proportion of
EtG-negative samples during CM. EtG has potential to personalize treatment for adults with
alcohol use disorders. For those unlikely to respond to a typical CM intervention,
modifications such as increasing the magnitude of reinforcement or requiring reductions in
drinking before abstinence might improve outcomes. Alternatively, other interventions such
as medication management may be needed to improve outcomes for CM non-responders.
Future research should investigate whether pre-treatment EtG levels predict outcomes in
other psychosocial and pharmacological interventions, and strategies for improving the
efficacy of CM for heavy drinkers.
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